Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Matthias Machacek"'
Autor:
Matthias Machacek, Elena Garcia-Montoya, Peter McColgan, Patricia Sanwald-Ducray, Norman Alan Mazer
Publikováno v:
Frontiers in Neuroscience, Vol 18 (2024)
The concentrations of neurofilament light chain (NfL) in cerebrospinal fluid (CSF) and plasma have become key biomarkers of many neurodegenerative diseases, including Huntington's Disease (HD). However, the relationship between the dynamics of NfL co
Externí odkaz:
https://doaj.org/article/9e7cdeb91adf409f83d530e86d1089e6
Autor:
Katherine Griffiths, Uli Binder, William McDowell, Rita Tommasi, Mark Frigerio, William G. Darby, Chris G. Hosking, Lionel Renaud, Matthias Machacek, Peter Lloyd, Arne Skerra, Michael Foley
Publikováno v:
mAbs, Vol 11, Iss 7, Pp 1331-1340 (2019)
Single domain antibodies that combine antigen specificity with high tissue penetration are an attractive alternative to conventional antibodies. However, rapid clearance from the bloodstream owing to their small size can be a limitation of therapeuti
Externí odkaz:
https://doaj.org/article/7654a6ff13a34f68ab979ca90ac88158
Publikováno v:
PLoS Computational Biology, Vol 16, Iss 10 (2020)
The complement system is a powerful mechanism of innate immunity poised to eliminate foreign cells and pathogens. It is an intricate network of >35 proteins, which, once activated, leads to the tagging of the surface to be eliminated, produces potent
Externí odkaz:
https://doaj.org/article/e52604fdad974a898ba411b5b2acef65
Autor:
Christine Voors-Pette, Lionel Renaud, Martine Jandrot Perrus, Philippe Billiald, Peter Dogterom, Yannick Pletan, Kristell Lebozec, Matthias Machacek
Publikováno v:
Journal of Clinical Pharmacology
Glenzocimab (ACT017) is a humanized monoclonal antigen‐binding fragment (Fab) directed against the human platelet glycoprotein VI, a key receptor for collagen and fibrin that plays a major role in thrombus growth and stability. Glenzocimab is being
Autor:
Federico Bolognani, Matthias Machacek, Annelieke Kruithof, Marieke de Kam, Kirsten Bergmann, Max van Gent, Matthias Moerland, Pascal Crenn, Christian Meyer, Gerard Greig, Pim Gal, Pascal Schulthess
Publikováno v:
Transplantation. 106:S544-S544
Autor:
Michael Foley, Rita Tommasi, Katherine Merne Griffiths, Mark Frigerio, Matthias Machacek, Lionel Renaud, Arne Skerra, Uli Binder, William G. Darby, William McDowell, Christopher G. Hosking, Peter Lloyd
Publikováno v:
mAbs
Single domain antibodies that combine antigen specificity with high tissue penetration are an attractive alternative to conventional antibodies. However, rapid clearance from the bloodstream owing to their small size can be a limitation of therapeuti
Autor:
Pauline Ferlan, Yannick Pletan, Philippe Billiald, Kristell Lebozec, Lionel Renaud, Gilles Avenard, Laurie Jullien, Matthias Machacek, Christine Voors-Pette, Martine Jandrot-Perrus, Olivier Favre-Bulle, Peter Dogterom
Publikováno v:
Arteriosclerosis, Thrombosis, and Vascular Biology. 39:956-964
Objective— ACT017 is a novel, first in class, therapeutic antibody to platelet GPVI (glycoprotein VI) with potent and selective antiplatelet effects. This first-in-human, randomized, placebo-controlled phase 1 study was conducted to evaluate the sa
Publikováno v:
PLoS Computational Biology, Vol 16, Iss 10, p e1008139 (2020)
PLoS Computational Biology
PLoS Computational Biology
The complement system is a powerful mechanism of innate immunity poised to eliminate foreign cells and pathogens. It is an intricate network of >35 proteins, which, once activated, leads to the tagging of the surface to be eliminated, produces potent
Autor:
Rossella Cardin, Rajesh Odedra, Cedric Charrier, Matthias Machacek, Samantha Franzoni, Adam Belley, Peter Warn, Sylvie Sordello, Philipp Knechtle, Fabian Bernhard
Publikováno v:
Antimicrob Agents Chemother
Third-generation cephalosporin (3GC)-resistant Enterobacteriaceae are classified as critical priority pathogens, with extended-spectrum β-lactamases (ESBLs) as principal resistance determinants. Enmetazobactam (formerly AAI101) is a novel ESBL inhib
Autor:
Matthias Machacek, Peter Lloyd, Andrew J. Pierce, Mark Maginn, Albert Chau, Julia Tilson, Sultanah Rajbally, Phillip Bartlett, Jannik Vollmer, Phil Bland-Ward, Kenji Hashimoto
Publikováno v:
Cancer Research. 81:CT206-CT206
T cell redirecting therapy, including bispecific antibodies, is a proven anti-cancer treatment modality. Humabodies* are fully human VH antibody components that can be connected by a short peptide linker to make multi-specific molecules. Preclinical